Collaboration to deliver new plasma collection platform

Terumo Blood and Cell Technologies and CSL Plasma collaborate to deliver a new plasma collection platform at CSL Plasma U.S. collection centers. A clinical trial of the investigational plasmapheresis device began earlier in April 2021, and introduction of the new platform is subject to U.S. Food and Drug Administration device clearance, at which time the parties will provide further comment.

Plasma is a key ingredient for therapies crucial to treating patients around the world suffering from a host of life-threatening conditions, such as HAE, primary immune deficiencies, autoimmune diseases, hemophilia and inherited respiratory disease. Plasma is also commonly given to patients experiencing trauma, burns and organ transplant surgeries.
(Source: Terumo)

2021-04-20T15:38:56+02:00April 20, 2021|HAEi News|